Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1806 | Sirolimus | 2 | 72 | 1.0 | 9238.3 | 12104.5 | 1643.3 | 0.0 | 0.821 | 0.763 | 2.881 | HCC1806 Rapamycin 0 2 72 |
| HCC1806 | Sirolimus | 2 | 72 | 0.32 | 8965.0 | 12104.5 | 1643.3 | -0.495 | 0.802 | 0.741 | 2.881 | HCC1806 Rapamycin 0 2 72 |
| HCC1806 | Sirolimus | 2 | 72 | 0.1 | 9292.5 | 12104.5 | 1643.3 | -1.0 | 0.825 | 0.768 | 2.881 | HCC1806 Rapamycin 0 2 72 |
| HCC1806 | Sirolimus | 2 | 72 | 0.032 | 9181.8 | 12104.5 | 1643.3 | -1.49 | 0.817 | 0.759 | 2.881 | HCC1806 Rapamycin 0 2 72 |
| HCC1806 | Sirolimus | 2 | 72 | 0.01 | 9275.5 | 12104.5 | 1643.3 | -2.0 | 0.823 | 0.766 | 2.881 | HCC1806 Rapamycin 0 2 72 |
| HCC1806 | Sirolimus | 2 | 72 | 0.0032 | 9333.0 | 12104.5 | 1643.3 | -2.49 | 0.827 | 0.771 | 2.881 | HCC1806 Rapamycin 0 2 72 |